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Antimicrobial resistance in Yersinia pestis is rare, yet constitutes a significant international public health and biodefense
threat. In 1995, the first multidrug resistant (MDR) isolate of Y. pestis (strain IP275) was identified, and was shown to contain
a self-transmissible plasmid (pIP1202) that conferred resistance to many of the antimicrobials recommended for plague
treatment and prophylaxis. Comparative analysis of the DNA sequence of Y. pestis plasmid pIP1202 revealed a near identical
IncA/C plasmid backbone that is shared by MDR plasmids isolated from Salmonella enterica serotype Newport SL254 and the
fish pathogen Yersinia ruckeri YR71. The high degree of sequence identity and gene synteny between the plasmid backbones
suggests recent acquisition of these plasmids from a common ancestor. In addition, the Y. pestis pIP1202-like plasmid
backbone was detected in numerous MDR enterobacterial pathogens isolated from retail meat samples collected between
2002 and 2005 in the United States. Plasmid-positive strains were isolated from beef, chicken, turkey and pork, and were found
in samples from the following states: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York
and Oregon. Our studies reveal that this common plasmid backbone is broadly disseminated among MDR zoonotic pathogens
associated with agriculture. This reservoir of mobile resistance determinants has the potential to disseminate to Y. pestis and
other human and zoonotic bacterial pathogens and therefore represents a significant public health concern.
Citation: Welch TJ, Fricke WF, McDermott PF, White DG, Rosso M, et al (2007) Multiple Antimicrobial Resistance in Plague: An Emerging Public Health
Risk. PLoS ONE 2(3): e309. doi:10.1371/journal.pone.0000309
INTRODUCTION
Yersinia pestis, the etiological agent of plague, is a zoonotic bacterial
pathogen that has caused multiple pandemics resulting in an
estimated 200 million human deaths [1]. Plague has recently been
recognized as a re-emerging disease as small outbreaks continue to
occur globally [2]. This reappearance, coupled with its potential
for aerosol dissemination and associated high mortality rate, also
makes Y. pestis one of the most dangerous bioterrorism agents [3].
Antimicrobial resistance in Y. pestis is rare but constitutes
a significant public health threat given that antimicrobials are
critical both for plague treatment and prevention of human-to-
human transmission. Furthermore, no vaccine is currently avail-
able. Thus, multidrug resistant (MDR) Y. pestis would likely have
a major human health impact, complicating the control of out-
breaks and leading to high mortality rates. Accordingly, the
isolation of a MDR Y. pestis strain (IP275) in 1995 caused
considerable alarm in the public health and biodefense commu-
nities [4,5]. Strain IP275 was isolated from a bubonic plague
patient in Madagascar and was shown to contain a self-trans-
missible plasmid (pIP1202) that conferred high-level resistance to
at least eight antimicrobials, including streptomycin, tetracycline,
chloramphenicol and sulfonamides, drugs recommended for
plague prophylaxis and therapy [3]. This is the only documented
case of MDR Y. pestis, although resistance monitoring of this
organism is not conducted systematically [4].
Recently there also has been a rapid worldwide emergence of
MDR foodborne bacterial pathogens [6,7]. While these resistant
variants can be transferred to humans via contaminated food
supplies, subsequent infections usually result in a self-limited
gastroenteritis that does not require antimicrobial therapy [8].
However, since these MDR determinants are often encoded on
mobile plasmids, the potential transfer of MDR phenotypes from
foodborne pathogens to more virulent human pathogens, in-
cluding Y. pestis, constitutes a serious public health threat.
Here we report the complete sequence and comparative analysis
of three nearly identical large (.150 kb) MDR plasmids isolated
from Yersinia pestis [5], Salmonella enterica ser. Newport and Yersinia
ruckeri. Our findings indicate a very recent common origin for these
plasmids. Moreover, we present evidence that a common plasmid
backbone is prevalent among E. coli, Klebsiella sp. and multiple
Salmonella serotypes isolated from retail meats in the US, and
among some food animal isolates of E. coli. Our data imply that
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evolve naturally, and present a vital biomedical, public health, and
biodefense threat.
RESULTS AND DISCUSSION
Comparative analysis of the complete DNA sequence of the Y.
pestis pIP1202 plasmid (182,913 bp) revealed a shared IncA/C
plasmid backbone of 113,320 bp with MDR plasmids pSN254
(176,473 bp) and pYR1 (158,038 bp) isolated respectively from
the foodborne pathogen Salmonella Newport SL254 and the fish
pathogen Yersinia ruckeri YR71 (Fig. 1). The shared backbone
regions (99-100% nucleotide identity) consist of 135 syntenic genes
with similar codon usage that encode functions such as plasmid
replication/maintenance and type IV conjugative transfer (25
genes). A total of 85 genes have no assigned function. Notably, the
backbone also includes a gene (sul2) conferring resistance to
sulfonamides, a class of synthetic antimicrobials first introduced
into clinical use in the 1930’s, suggesting that these plasmids
evolved from the same sulfonamide resistant ancestor. All other
antimicrobial resistance determinants are integrated at four sites
comprising laterally acquired DNA as shown by the deviating
nucleotide composition of these regions (Fig. 1). Each plasmid also
carries a laterally acquired region integrated at either side of a gene
containing repetitive sequences of the RHS type [9], which may
act as an integration hotspot for acquired DNA. A large fraction of
antimicrobial resistance genes are encoded within either of two
transposons, Tn21 and Tn10 (Fig. 1). A region in pSN254
contains duplicate copies of the blaCMY-2 gene. The number of
resistance determinants varies with four on pYR1, ten on pIP1202
and 13 on pSN254, several of which are present in multiple copies
(Table 1 and Fig. 1). In addition, both pIP1202 and pSN254 carry
Figure 1. Circular representation of the IncA/C backbone (inner circle) and laterally acquired regions (outer circles) on each of the three
plasmids. Nucleotide composition is represented on each of the outer circles and PCR primers used in this study are indicated in the inner circle.
Antimicrobial determinants are colored red and labeled with gene names as follows: sulfonamides (sul1, sul2); phenicols (cat, floR); tetracyclines
(tetRA); aminoglycosides/aminocyclitols (aacC, aadA, aphA, strAB); quaternary ammonium compounds (qacEdelta1, sugE1, sugE2); b-lactams (blaCMY-
2-1, blaCMY-2-2, blaSHV-1); trimethoprim (dhfrI); mercury ions (merRTPABDE, merRTPCADE). Sequences described in this manuscript have been
deposited in GenBank, accession numbers are CP000603 (pIP1202), CP000604 (pSN254), CP000602 (pYR1).
doi:10.1371/journal.pone.0000309.g001
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family [10].
While MDR Y. pestis and Y. ruckeri isolates are rarely reported,
monitoring of antimicrobial resistance in Salmonella has shown an
escalating incidence of MDR strains resistant to an increasing
number of drugs (i.e.$eight antimicrobials) [11]. Moreover, S.
Newport MDR strains harboring plasmids encoding resistance to
expanded-spectrum cephalosporins (Newport MDR-AmpC phe-
notype) are widely disseminated within the United States and have
been isolated from cattle, ground beef and ill humans [12]. As
plasmid pSN254 confers the Newport MDR-AmpC resistance
phenotype, we sought to determine the occurrence and distribu-
tion of the IncA/C plasmid backbone among 125 MDR Salmonella
strains recovered from retail meats from 2002 to 2005 through the
National Antimicrobial Resistance Monitoring System (NARMS
see cite above), as well as a small collection of E. coli strains
recovered from food animals and Klebsiella isolates from ground
turkey meat from Iowa. Using the repA gene as marker, primary
screening by PCR for the IncA/C replicon [13] revealed 70 repA-
positive samples that were subsequently probed with a panel of
twelve PCR assays targeting backbone regions (shown in Fig. 1).
These findings indicated that IncA/C plasmid backbones were
present in all repA-positive strains, in all meat types sampled,
including chicken, turkey, pork and ground beef and in all ten
states that participate in the NARMS retail surveillance (Table 2).
Several IncA/C positive strains were found in California, New
Mexico and Oregon, areas of the United States where Y. pestis is
endemic. IncA/C backbones were detected in representatives of S.
enterica Newport, Heidelberg, Kentucky, Dublin, Bredeney, and
Typhimurium. In addition, screening of E. coli and Klebsiella MDR
isolates revealed the presence of this plasmid backbone in the nine
tested Klebsiella isolates recovered from ground turkey collected in
Iowa, and E. coli isolated from a calf in North Dakota and a broiler
chicken from Georgia (Table 2). A majority of S. Newport and S.
Heidelberg strains (9/14) and several Klebsiella isolates (3/9) were
positive for all twelve markers, while other Salmonella serotypes
were positive for 50% or greater of the assayed loci (Table 2).
The discovery of these MDR IncA/C plasmids in evolutionarily
distinct pathogens attests to recent genetic exchange, either
directly between these bacterial species or through bacterial
intermediates, and it suggests that overlap in the ecological niches
of these organisms is sufficient to permit past or future plasmid
transmission. This is consistent with the high identity (60 kb, 97%
nucleotide identity) found between Y. pestis virulence plasmid pFra
and S. enterica Typhi plasmid pHMC2 [14,15]. The ecological
location of plasmid transfer to Y. pestis is unknown, although it has
been speculated that transfer might occur in a co-infected
mammalian host or in the midgut of the flea [16], the classic
vector for plague. Recent experimental evidence has shown that
high frequency transfer of a streptomycin resistant R-plasmid from
E. coli to Y. pestis can occur in flea midgut [17].
While identification of the exact bacterial donor or sequence of
events leading to the transfer of pIP1202 to Y. pestis cannot be
conclusively determined, we were able to demonstrate the transfer
of the IncA/C plasmids present in the 70 MDR repA+foodborne
enterics (Table 2) to Y. ruckeri. Thirty of the 70 MDR enterics
tested transferred drug resistance to Y. ruckeri along with the IncA/
C-specific repA marker. Interestingly, 53% (29/54) of the MDR
isolates from poultry products transferred resistance to Y. ruckeri
while only one of the 14 non-poultry isolates was transfer
competent. Conjugal transfer could not be demonstrated for
IncA/C plasmids from any of the S. Newport isolates identified,
including the sequenced SL254 isolate. In these cases transfer
might depend on the presence of additional transfer functions or
may be limited by incompatible restriction/modification systems.
In all, a large fraction of the repA+MDR enterics were capable of
transferring resistance, suggesting that direct transfer of IncA/C
MDR plasmids mediates environmental dissemination between
these bacterial genera.
Our findings reveal a potential for the natural acquisition of
multidrug resistance in Y. pestis and other MDR zoonotic bacterial
pathogens. Hence, antimicrobial resistance monitoring should be
expanded especially to the areas of the world where Y. pestis is
endemic, including Asia, Africa and the Southwestern United
States where both Y. pestis and MDR Salmonella have been isolated
and therefore have a high probability of coming into direct
contact. The plasmid detection and typing assays described here
could also be used to monitor pIP1202-like antimicrobial
resistance plasmids in numerous bacterial pathogens recovered
from diverse environments including animal production systems,
foods, and health care settings, and may be useful for the detection
of these plasmids in biothreat agents.
MATERIALS AND METHODS
Genome sequencing and Informatics
Plasmids pIP1202 and pSN254 were assembled from whole
genome shotgun sequencing of Y. pestis IP275 and S. enterica
serotype Newport SL254 respectively, while pYR1 was sequenced
from purified plasmid DNA. Sequencing libraries were con-
structed as previously reported [18] and sequenced using 3730xl
DNA analyzer (Applied Biosystems). Assembly and closure,
Table 1. Antimicrobial resistance determinants.
..................................................................................................................................................
Backbone Y. pestis (pIP1202) S. enterica (pSN254) Y. ruckeri (pYR1)
Resistance phenotypes* Su ACKSSpTMSul ACSSulTCfAxG STTmSul
b-lactams - blaSHV-1 blaCMY-21, blaCMY-22 -
Aminoglycosides/Aminocyclitols - strAB, aadA, aphA strAB, aacC, aadA strAB
Tetracyclines - tetRAclass D tetRAclass A tetRAclass B
Phenicols - cat floR -
Quaternary ammonium compounds - qacEdelta1 qacEdelta1, sugE1, sugE2 -
Sulfonamides sul2 sul1, sul2 sul1, sul2 sul2
Trimethoprim - - - dhfrI
*Abbreviations used for antibiotics: A, ampicillin; C, chloramphenicol; S, streptomycin; Sul, sulfonamide; T, tetracycline; Cf, cephalothin, Ax, ceftriaxone; G, gentamicin;
Sp, spectinomycin; M, minocycline; Tm, trimethoprim.
doi:10.1371/journal.pone.0000309.t001
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described [18].
PCR screening
Plasmid DNA for PCR was prepared using the QIAprep Spin
Miniprep kit according to the manufacturer’s procedure (Qiagen).
PCR was performed using HotStarTaq (Qiagen) with the
following cycling protocol: five min enzyme activation at 95uC,
26 cycles of 45 s at 95uC, 45 s at 55uC and 90 s at 72uC followed
by a 10 min final extension step at 72uC. The 13 primer sets used
were designed to each amplify a distinct plasmid backbone region
displayed in Fig. 1. Primers used are listed in Supplemental
Methods S1.
Plasmid transfer experiments
Conjugative mating experiments were performed using a rifampi-
cin resistant derivative of Y. ruckeri (YR34R) as the recipient strain.
Donor (Table 2) and recipient strains were grown in an orbital
shaker (225 rpm) in Brain-Heart-Infusion (BHI) medium at 37uC
(donor) or 28uC (recipient) to mid-log phase. Donor and recipient
bacteria were then harvested by centrifugation (60006g, 10 min,
4uC) and 10
8 of each were mixed and spotted onto BHI agar.
Conjugation mixtures were allowed to incubate for 3 h at 28uC
after which the cells were resuspended in PBS, diluted, and plated
onto BHI agar containing tetracycline (20 mg/ml) for plasmid
selection and rifampicin (100 mg/ml) to counter select the donor.
For donor strains that did not transfer tetracycline resistance,
conjugations were repeated using selection for ampicillin (100 mg/
ml), ceftriaxone (8 mg/ml), chloramphenicol (100 mg/ml), and
kanamycin (50mg/ml). Transconjugants were confirmed using a Y.
ruckeri-specific bacteriophage and assayed for the presence of the
repA marker by PCR as described above.
SUPPORTING INFORMATION
Methods S1 Primers used in this study
Found at: doi:10.1371/journal.pone.0000309.s001 (0.03 MB
DOC)
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